For: |
Cui J, Dong BW, Liang P, Yu XL, Yu DJ. Effect of c- |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v10/i10/1533.htm |
Number | Citing Articles |
1 |
Zhuo Zhang, Mao Li, Elizabeth R Rayburn, Donald L Hill, Ruiwen Zhang, Hui Wang. Oncogenes as Novel Targets for Cancer Therapy (Part III). American Journal of PharmacoGenomics 2005; 5(5): 327 doi: 10.2165/00129785-200505050-00005
|
2 |
Mona Moussa, Noha Helal, Enas Elnahas, Samar El-Sheikh, Dalal Alwi. Correlation of hepatic expression of Ki-67 and metallothionein with iron load in chronic hepatitis C and hepatocellular carcinoma. Current Medicine Research and Practice 2018; 8(6): 209 doi: 10.1016/j.cmrp.2018.10.002
|
3 |
Yulong Han, Qiuzhong Pan, Zhixing Guo, Yufei Du, Yaojun Zhang, Yingying Liu, Jingjing Zhao, Jinfeng Xu, Jieying Yang, Dijun Ouyang, Yan Tang, Qijing Wang, Yongqiang Li, Jia He, Mengjuan Yang, Hao Chen, Chaopin Yang, Xinyi Yang, Jinqi You, Yuanyuan Chen, Minghao Ren, Yao Zhu, Jianchuan Xia, Tong Xiang. BMP9‐induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus‐associated hepatocellular carcinoma. Clinical and Translational Medicine 2023; 13(5) doi: 10.1002/ctm2.1247
|
4 |
Mohamed Abd-Elbaset, Ahmed M. Mansour, Osama M. Ahmed, Amira M. Abo-Youssef. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways. Naunyn-Schmiedeberg's Archives of Pharmacology 2020; 393(9): 1611 doi: 10.1007/s00210-020-01863-9
|
5 |
|
6 |
Brian I. Carr. Hepatocellular carcinoma: Current management and future trends. Gastroenterology 2004; 127(5): S218 doi: 10.1053/j.gastro.2004.09.036
|
7 |
Fabio Farinati, Dario Marino, Massimo De Giorgio, Anna Baldan, Maria Cantarini, Carmela Cursaro, Gianludovico Rapaccini, Paolo Del Poggio, Maria Anna Di Nolfo, Luisa Benvegnu, Marco Zoli, Franco Borzio, Mauro Bernardi, Franco Trevisani. Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?. The American Journal of Gastroenterology 2006; 101(3): 524 doi: 10.1111/j.1572-0241.2006.00443.x
|
8 |
Matthias Pinter, Wolfgang Sieghart, Monika Schmid, Bernhard Dauser, Gerald Prager, Hans Peter Dienes, Michael Trauner, Markus Peck‐Radosavljevic. Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF‐A expression in hepatocellular carcinoma. United European Gastroenterology Journal 2013; 1(4): 265 doi: 10.1177/2050640613496605
|
9 |
Stephanie Coulon, Femke Heindryckx, Anja Geerts, Christophe Van Steenkiste, Isabelle Colle, Hans Van Vlierberghe. Angiogenesis in chronic liver disease and its complications. Liver International 2011; 31(2): 146 doi: 10.1111/j.1478-3231.2010.02369.x
|
10 |
Valtteri Kairaluoma, Niko Kemi, Heikki Huhta, Vesa‐Matti Pohjanen, Olli Helminen. Toll‐like receptor 5 and 8 in hepatocellular carcinoma. APMIS 2021; 129(8): 470 doi: 10.1111/apm.13142
|
11 |
Jun Muto, Ken Shirabe, Keishi Sugimachi, Yoshihiko Maehara. Review of angiogenesis in hepatocellular carcinoma. Hepatology Research 2015; 45(1): 1 doi: 10.1111/hepr.12310
|
12 |
Mariana V. Machado, Helena Cortez-Pinto. Proangiogenic factors in the development of HCC in alcoholic cirrhosis. Clinics and Research in Hepatology and Gastroenterology 2015; 39: S104 doi: 10.1016/j.clinre.2015.06.001
|
13 |
WENHUAN HUANG, CHENG CHEN, ZHONGHENG LIANG, JUNLU QIU, XINXIN LI, XIANG HU, SHUANGLIN XIANG, XIAOFENG DING, JIAN ZHANG. AP-2α inhibits hepatocellular carcinoma cell growth and migration. International Journal of Oncology 2016; 48(3): 1125 doi: 10.3892/ijo.2016.3318
|
14 |
Ashish Singhal, Muralidharan Jayaraman, Danny N. Dhanasekaran, Vivek Kohli. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012; 82(2): 116 doi: 10.1016/j.critrevonc.2011.05.005
|
15 |
Nabil M. Abdel-Hamid, Sherin Zakaria, Reem A. Nawaya, Ramadan A. Eldomany, Mamdouh M. El-Shishtawy. Daidzein and Chicory Extract Arrest the Cell Cycle via Inhibition of
Cyclin D/CDK4 and Cyclin A/CDK2 Gene Expression in Hepatocellular
Carcinoma. Recent Patents on Anti-Cancer Drug Discovery 2023; 18(2): 187 doi: 10.2174/1574892817666220321161318
|
16 |
Zhengbin Zhang, Dylan Harris, Virendra N. Pandey. The FUSE Binding Protein Is a Cellular Factor Required for Efficient Replication of Hepatitis C Virus. Journal of Virology 2008; 82(12): 5761 doi: 10.1128/JVI.00064-08
|
17 |
T Scheller, C Hellerbrand, C Moser, K Schmidt, A Kroemer, S M Brunner, H J Schlitt, E K Geissler, S A Lang. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. British Journal of Cancer 2015; 112(5): 841 doi: 10.1038/bjc.2014.638
|
18 |
Yunqing Yin, Wei Zhang, Yanhui Chen, Yanfang Zhang, Xinying Shen. Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: Current status and challenges. Heliyon 2024; 10(23): e40588 doi: 10.1016/j.heliyon.2024.e40588
|
19 |
Dandan Huang, Weiyun Zhang, Danqing Huang, Jianyong Wu. Antitumor Activity of the Aqueous Extract from Sedum sarmentosum Bunge In Vitro. Cancer Biotherapy and Radiopharmaceuticals 2010; 25(1): 81 doi: 10.1089/cbr.2009.0632
|
20 |
Andrew X. Zhu, Dan G. Duda, Dushyant V. Sahani, Rakesh K. Jain. HCC and angiogenesis: possible targets and future directions. Nature Reviews Clinical Oncology 2011; 8(5): 292 doi: 10.1038/nrclinonc.2011.30
|
21 |
A. Altadill, M. Rodríguez, L.O. González, S. Junquera, M.D. Corte, M.L. González-Dieguez, A. Linares, E. Barbón, M. Fresno-Forcelledo, L. Rodrigo, F.J. Vizoso. Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Digestive and Liver Disease 2009; 41(10): 740 doi: 10.1016/j.dld.2009.01.016
|
22 |
Jinyu Yang, Weiyun Zhang, Peihua Shi, Jiaping Chen, Xiaodong Han, Yong Wang. Effects of exopolysaccharide fraction (EPSF) from a cultivated Cordyceps sinensis fungus on c-Myc, c-Fos, and VEGF expression in B16 melanoma-bearing mice. Pathology - Research and Practice 2005; 201(11): 745 doi: 10.1016/j.prp.2005.08.007
|
23 |
Jian Kong, Jinge Kong, Bing Pan, Shan Ke, Shuying Dong, Xiuli Li, Aimin Zhou, Lemin Zheng, Wen-bing Sun, Mercedes Susan Mandell. Insufficient Radiofrequency Ablation Promotes Angiogenesis of Residual Hepatocellular Carcinoma via HIF-1α/VEGFA. PLoS ONE 2012; 7(5): e37266 doi: 10.1371/journal.pone.0037266
|
24 |
Liyuan Li, Maoxiang Qian, I-Hsuan Chen, David Finkelstein, Arzu Onar-Thomas, Melissa Johnson, Christopher Calabrese, Armita Bahrami, Dolores H. López-Terrada, Jun J. Yang, W. Andy Tao, Liqin Zhu. Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice. The American Journal of Pathology 2018; 188(3): 656 doi: 10.1016/j.ajpath.2017.11.013
|
25 |
Ahmed O. Kaseb, Amr Hanbali, Matthew Cotant, Manal M. Hassan, Ira Wollner, Philip A. Philip. Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer 2009; 115(21): 4895 doi: 10.1002/cncr.24537
|
26 |
Çağri Öner, Dilara Soyergin, Ahmet Özyurt, Ertuğrul Çolak. 4-Hydroxycoumarin Effects on Both Cellular and Genetic Characteristics of Hepatocellular Carcinoma Cells. Cytology and Genetics 2022; 56(3): 292 doi: 10.3103/S0095452722030094
|
27 |
Mariana V. Machado, André Janeiro, Gabriel Miltenberger-Miltenyi, Helena Cortez-Pinto. Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis. European Journal of Gastroenterology & Hepatology 2014; 26(4): 438 doi: 10.1097/MEG.0000000000000044
|
28 |
Jonathan Whisenant, Emily Bergstand. Anti-angiogenic strategies in gastrointestinal malignancies. Current Treatment Options in Oncology 2005; 6(5): 411 doi: 10.1007/s11864-005-0044-8
|
29 |
Elena Mocanu, V. Broască, Beatrice Severin. Ki-67 Expression In Hepatocellular Carcinoma Developed On A Liver Cirrhosis. ARS Medica Tomitana 2012; 18(1): 33 doi: 10.2478/v10307-012-0006-x
|
30 |
MING-TA SUNG, HUI-TZU HSU, CHIH-CHUN LEE, HSIN-CHEN LEE, YING-JU KUO, KATE HUA, CHENG-YUAN HSIA, CHIN-WEN CHI. Krüppel-like factor 4 modulates the migration and invasion of hepatoma cells by suppressing TIMP-1 and TIMP-2. Oncology Reports 2015; 34(1): 439 doi: 10.3892/or.2015.3964
|
31 |
Christopher D. Mann, Christopher P. Neal, Giuseppe Garcea, Margaret M. Manson, Ashley R. Dennison, David P. Berry. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer 2007; 43(6): 979 doi: 10.1016/j.ejca.2007.01.004
|
32 |
Melanie B. Thomas, Jeffrey S. Morris, Romil Chadha, Michiko Iwasaki, Harmeet Kaur, Elinor Lin, Ahmed Kaseb, Katrina Glover, Marta Davila, James Abbruzzese. Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology 2009; 27(6): 843 doi: 10.1200/JCO.2008.18.3301
|
33 |
Ahmed O. Kaseb, Jeffrey S. Morris, Manal M. Hassan, James L. Abbruzzese. Reply to A. Goyal et al. Journal of Clinical Oncology 2012; 30(9): 1019 doi: 10.1200/JCO.2011.40.9375
|
34 |
Fei Ji, Zhi-heng Zhang, Yi Zhang, Shun-Li Shen, Qing-Hua Cao, Long-Juan Zhang, Shao-Qiang Li, Bao-Gang Peng, Li-Jian Liang, Yun-Peng Hua. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4379-5
|
35 |
Kazuhisa Kaneda, Takahiro Uenishi, Shigekazu Takemura, Hiroji Shinkawa, Yorihisa Urata, Masayuki Sakae, Takatsugu Yamamoto, Shoji Kubo. The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus‐related hepatocellular carcinoma. Journal of Surgical Oncology 2012; 105(6): 606 doi: 10.1002/jso.22137
|
36 |
A.I. Faustino-Rocha, A. Silva, J. Gabriel, R.M. Gil da Costa, M. Moutinho, P.A. Oliveira, A. Gama, R. Ferreira, M. Ginja. Long-term exercise training as a modulator of mammary cancer vascularization. Biomedicine & Pharmacotherapy 2016; 81: 273 doi: 10.1016/j.biopha.2016.04.030
|
37 |
Roberta Pang, Ronnie T.P. Poon. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Letters 2006; 242(2): 151 doi: 10.1016/j.canlet.2006.01.008
|
38 |
F. AZZAROLI, A. COLECCHI, F. LODATO, D. TRERÈ, M. L. BACCHI REGGIANI, D. FESTI, G. M. PRATI, E. ACCOGLI, S. CASANOVA, M. DERENZINI, E. RODA, G. MAZZELLA. A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis. Alimentary Pharmacology & Therapeutics 2006; 24(1): 129 doi: 10.1111/j.1365-2036.2006.02955.x
|
39 |
Sean R. Rudnick, Mark W. Russo. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2018; 12(3): 265 doi: 10.1080/17474124.2018.1417035
|
40 |
Ron C. Gaba, John V. Groth, Ahmad Parvinian, Grace Guzman, Leigh C. Casadaban. Gene Expression in Hepatocellular Carcinoma: Pilot Study of Potential Transarterial Chemoembolization Response Biomarkers. Journal of Vascular and Interventional Radiology 2015; 26(5): 723 doi: 10.1016/j.jvir.2014.12.610
|
41 |
Ahlam A. Abd Elmaksoud, Taghreed A.E. Abd Elazee. Role of c-Myc and CD34 oncoproteins expression in early and late phases of hepatocarcinogenesis. Egyptian Journal of Pathology 2011; 31(1): 25 doi: 10.1097/01.XEJ.0000398108.88640.3f
|
42 |
Weidong Jia, Kehai Feng, Pingsheng Fan, Gaofei Fan, Shoumei Yang, Tengyue Zhang, Qiang Wei, Liting Qian. Post-TACE Combination Therapy of Heparin and Octreotide Results in Decreased Tumor Metastasis in Extrahepatic Tumorigenesis. Cell Biochemistry and Biophysics 2012; 62(1): 35 doi: 10.1007/s12013-011-9255-8
|